Assessing glycemia in type 1 diabetic patients using a microdialysis system for continuous glucose monitoring

Continuous glucose monitoring systems can monitor moment-to-moment changes in blood glucose concentration, which cannot be detected by intermittent self-monitoring. Continuing monitoring systems may lead to improved glycemic control. We evaluated a microdialysis technique for improving glycemic control in type 1 diabetes patients treated by different means of basal insulin substitution. Fifty-two type 1 diabetic patients on twice daily NPH and pre-meal aspart insulin were randomized in two groups: the continuation of NPH [n=26] [group 1] or once daily glargine [n=26] [group 2]. 48-hour GlucoDay registrations were started at the beginning and after 4 months. At baseline, time spent in the euglycemic range [glucose between 3.9 and 8.0mmol/L] was 37.96 +/- 6.81% for the NPH group and 35.83 +/- 6.24% for the glargine group. At endpoint, time in the euglycemic range increased in both groups [51.02 +/- 7.22% and 57.29 +/- 10.27%, P<0.001 vs. before treatment for both groups]. Time spent in the hypoglycemic range [glucose <3.9 mmol/L] was 9.98 +/- 2.57% for the first group and 10.24 +/- 3.55% for the second group at baseline. At endpoint, time in the hypoglycemic range decreased in both groups [8.00 +/- 2.13% and 6.59 +/- 2.04%, P<0.001 vs. before treatment for both groups]. The analysis of the GlucoDay data gave us information about glycemia other than HbA1c and self-monitoring of blood glucose, such us a peakless activity profile and the lower percentage of time spent in the hypoglycemic range in the glargine-treated group